Stratos Wealth Partners’s abrdn Life Sciences Investors HQL Stock Holding History
Bought
Maintained
Sold
Other funds holding HQL
SCM
PCM
NIM
FHA
RCM
Stratos Wealth Partners's HQL Position: Q1 2026 in Review
Stratos Wealth Partners increased its abrdn Life Sciences Investors (HQL) stake by 6.5% in Q1 2026, buying an estimated $16.4K and bringing the position to 16,104 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.
Stratos Wealth Partners first reported a position in HQL in Q4 2017 and has held it in 23 quarters since. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.
- Stratos Wealth Partners held 16,104 shares of abrdn Life Sciences Investors worth $262K as of Q1 2026.
- Stratos Wealth Partners bought 980 abrdn Life Sciences Investors shares in Q1 2026, an estimated $16.4K.
- abrdn Life Sciences Investors made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q1 2026, its #1397 holding.
- Stratos Wealth Partners first reported a position in abrdn Life Sciences Investors in Q4 2017 and has held it in 23 quarters since.
- 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.
Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.